Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
ACS Chem Neurosci ; 9(6): 1290-1303, 2018 06 20.
Article in English | MEDLINE | ID: mdl-29473731

ABSTRACT

Multitargeting or polypharmacological approaches, looking for single chemical entities retaining the ability to bind two or more molecular targets, are a potentially powerful strategy to fight complex, multifactorial pathologies. Unfortunately, the search for multiligand agents is challenging because only a small subset of molecules contained in molecular databases are bioactive and even fewer are active on a preselected set of multiple targets. However, collections of natural compounds feature a significantly higher fraction of bioactive molecules than synthetic ones. In this view, we searched our library of 1175 natural compounds from marine sources for molecules including a 2-aminoimidazole+aromatic group motif, found in known compounds active on single relevant targets for Alzheimer's disease (AD). This identified two molecules, a pseudozoanthoxanthin (1) and a bromo-pyrrole alkaloid (2), which were predicted by a computational approach to possess interesting multitarget profiles on AD target proteins. Biochemical assays experimentally confirmed their biological activities. The two compounds inhibit acetylcholinesterase, butyrylcholinesterase, and ß-secretase enzymes in high- to sub-micromolar range. They are also able to prevent and revert ß-amyloid (Aß) aggregation of both Aß1-40 and Aß1-42 peptides, with 1 being more active than 2. Preliminary in vivo studies suggest that compound 1 is able to restore cholinergic cortico-hippocampal functional connectivity.


Subject(s)
Acetylcholinesterase/drug effects , Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/pharmacology , Ligands , Acetylcholinesterase/metabolism , Alzheimer Disease/metabolism , Amyloid Precursor Protein Secretases/drug effects , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Peptides/metabolism , Animals , Butyrylcholinesterase/drug effects , Butyrylcholinesterase/metabolism , Humans , Peptide Fragments/metabolism , Silicon
2.
J Alzheimers Dis ; 50(4): 1217-25, 2016.
Article in English | MEDLINE | ID: mdl-26757042

ABSTRACT

BACKGROUND: Pain is under-detected and undertreated in people with dementia. The present study investigates the prevalence of pain in people with dementia hospitalized in nursing homes that are members of National Association of Third Age Residences (ANASTE) Calabria, and evaluates the association among pain, mood, and behavioral and psychological symptoms of dementia (BPSD). OBJECTIVE: The aim of this study is to define the prevalence of pain in people with dementia in long term care facilities using scales of self-reporting and observational tools and, particularly, to study the relationship between pain and BPSD. METHODS: A prospective observational study was carried out on 233 patients. Pain assessment was performed using self-reporting tools such as the Numeric Rating Scale (NRS) for patients with slight cognitive impairment or no cognitive impairment and observational tools such as Pain Assessment In Advanced Dementia Scale (PAINAD) for patients with moderate or severe cognitive impairment. Mood was evaluated through the Cornell Scale for Depression in Dementia (CSDD) while behavioral problems were assessed through the Cohen-Mansfield Agitation Inventory (CMAI) and Neuropsychiatric Inventory (NPI). RESULTS: Only 42.5% of patients evaluated by NRS provided a reliable answer; of these, 20.4% reported no pain. The percentage of pain evaluated by PAINAD was 51.8% . Analysis of data showed a statistically significant correlation between diagnosis of pain and depressive symptoms, assessed with CSDD (p = 0.0113), as well as by single items of NPI, such as anxiety (p = 0.0362) and irritability (p = 0.0034), and F1 profile (Aggression) of CMAI (p = 0.01). CONCLUSION: This study confirms that self-report alone is not sufficient to assess pain in elderly people with dementia; the observational tool is a necessary and suitable way of assessing pain in patients with cognitive impairment. If not adequately treated, chronic pain can cause depression, agitation, and aggression in patients with dementia.


Subject(s)
Dementia/complications , Dementia/diagnosis , Pain Measurement/methods , Pain/complications , Pain/diagnosis , Affect , Aged, 80 and over , Analgesics/therapeutic use , Anxiety/complications , Anxiety/diagnosis , Anxiety/epidemiology , Anxiety/therapy , Dementia/epidemiology , Dementia/therapy , Depression/complications , Depression/diagnosis , Depression/epidemiology , Depression/therapy , Female , Humans , Italy/epidemiology , Logistic Models , Long-Term Care , Male , Multivariate Analysis , Nursing Homes , Pain/drug therapy , Pain/epidemiology , Prevalence , Prospective Studies , Psychiatric Status Rating Scales , Self Report , Severity of Illness Index
3.
Behav Brain Res ; 278: 155-66, 2015 Feb 01.
Article in English | MEDLINE | ID: mdl-25289489

ABSTRACT

One of the most peculiar characteristics of the stress response is the pronounced inter-individual and inter-strain variability both in behavioral and neurochemical outcomes. Several studies confirm that rodents belonging to the same or different strain and/or gender, when exposed to a stressor, may show behavioral and cognitive differences. We compared the effects of long-term betamethasone 21-phosphate disodium (BTM), a widely clinically used corticosteroid, on animal behavior and neurogenesis in CD1 and DBA/2 mice. BTM treatment, in CD1 mice, increased body weight gain and anxiety parameters while having pro-depressant effects. Furthermore, BTM significantly reduced neurogenesis in the dentate gyrus of the hippocampus. Finally, BTM treatment induced a significant impairment in memory and learning performance in the Morris water maze. At odds, BTM administration, in DBA/2 mice, caused a significant reduction in the body weight while not modifying anxiety parameters. In addition, both an increased synaptogenesis and neurogenesis were found. Similarly to CD1 mice, also in DBA/2 mice, memory and learning were impaired. Our data confirm that long-term exposure to corticosteroids can generate or aggravate psychiatric/neurologic disorders such as depression, anxiety, memory and learning. Our study did not reveal significant differences between corticosterone and BTM treatment in CD1 mice. In contrast, BTM treatment in mice with an anxious phenotype (DBA/2 mice) revealed some contrasting results indicating that genetic factors can influence corticosteroids dependent effects. Finally, our data further underline the need for a re-evaluation of neurogenesis role; the increased neurogenesis observed in DBA/2 mice and behavioral effects might be distinguished phenomena.


Subject(s)
Behavior, Animal/drug effects , Betamethasone/analogs & derivatives , Glucocorticoids/pharmacology , Neurogenesis/drug effects , Administration, Oral , Animals , Betamethasone/pharmacology , Body Weight/drug effects , Bromodeoxyuridine , Doublecortin Domain Proteins , Exploratory Behavior/drug effects , Feeding Behavior/drug effects , Male , Maze Learning/drug effects , Mice , Mice, Inbred Strains , Microtubule-Associated Proteins , Neurons/diagnostic imaging , Neurons/drug effects , Neuropeptides , Silver Staining , Species Specificity , Statistics, Nonparametric , Swimming/psychology , Time Factors , Ultrasonography
4.
Clin Interv Aging ; 9: 105-10, 2014.
Article in English | MEDLINE | ID: mdl-24453481

ABSTRACT

OBJECTIVE: The interaction between dementia and nutritional state is very complex and not yet fully understood. The aim of the present study was to assess the interaction between cognitive impairment and nutritional state in a cohort of residential elderly in relationship with functional condition of patients and their load of assistance in long-term-care facilities of the National Association of Third Age Structures (ANASTE) Calabria. METHODS: One hundred seventy-four subjects (122 female and 52 male) were admitted to the long-term-care ANASTE Calabria study. All patients underwent multidimensional geriatric assessment. Nutritional state was assessed with the Mini Nutritional Assessment (MNA), whereas cognitive performance was evaluated by the Mini-Mental State Examination (MMSE). The functional state was assessed by Barthel Index (BI) and Activity Daily Living (ADL). The following nutritional biochemical parameters were also evaluated: albumin, cholesterol, iron, and hemoglobin. All patients were reassessed 180 days later. RESULTS: A severe cognitive impairment in MMSE performance was displayed in 49.7% patients, while 39.8% showed a moderate deficit; 6.9% had a slight deficit; and 3.4% evidenced no cognitive impairment. In MNA, 30% of patients exhibited an impairment of nutritional state; 56% were at risk of malnutrition; and 14% showed no nutritional problems. Malnutrition was present in 42% of patients with severe cognitive impairment, but only 4% of malnourished patients showed moderate cognitive deficit. The statistical analysis displayed a significant correlation between MNA and MMSE (P<0.001), as did MMSE correlated with Activity Daily Living (P<0.001) and BI (P<0.05). MNA correlated with BI (P<0.001) and albumin (P<0.001). The follow-up showed a strong correlation between cognitive deterioration and worsening of nutritional state (P<0.005) as well as with the functional state (P<0.05) and mortality (P<0.01). CONCLUSION: The present study clearly shows that malnutrition may play an important role in the progression of cognitive loss.


Subject(s)
Activities of Daily Living , Cognition Disorders/complications , Long-Term Care/statistics & numerical data , Nutritional Status , Aged , Cognition Disorders/epidemiology , Cognitive Dysfunction/complications , Cognitive Dysfunction/epidemiology , Female , Humans , Italy/epidemiology , Male , Malnutrition/epidemiology , Malnutrition/etiology , Neuropsychological Tests , Nutrition Assessment , Prevalence
5.
PLoS One ; 8(11): e80852, 2013.
Article in English | MEDLINE | ID: mdl-24236205

ABSTRACT

The antiepileptic drug Levetiracetam (Lev) has neuroprotective properties in experimental stroke, cerebral hemorrhage and neurotrauma. In these conditions, non-convulsive seizures (NCSs) propagate from the core of the focal lesion into perilesional tissue, enlarging the damaged area and promoting epileptogenesis. Here, we explore whether Lev neuroprotective effect is accompanied by changes in NCS generation or propagation. In particular, we performed continuous EEG recordings before and after the permanent occlusion of the middle cerebral artery (pMCAO) in rats that received Lev (100 mg/kg) or its vehicle immediately before surgery. Both in Lev-treated and in control rats, EEG activity was suppressed after pMCAO. In control but not in Lev-treated rats, EEG activity reappeared approximately 30-45 min after pMCAO. It initially consisted in single spikes and, then, evolved into spike-and-wave and polyspike-and-wave discharges. In Lev-treated rats, only rare spike events were observed and the EEG power was significantly smaller than in controls. Approximately 24 hours after pMCAO, EEG activity increased in Lev-treated rats because of the appearance of polyspike events whose power was, however, significantly smaller than in controls. In rats sacrificed 24 hours after pMCAO, the ischemic lesion was approximately 50% smaller in Lev-treated than in control rats. A similar neuroprotection was observed in rats sacrificed 72 hours after pMCAO. In conclusion, in rats subjected to pMCAO, a single Lev injection suppresses NCS occurrence for at least 24 hours. This electrophysiological effect could explain the long lasting reduction of ischemic brain damage caused by this drug.


Subject(s)
Anticonvulsants/pharmacology , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/pathology , Piracetam/analogs & derivatives , Seizures/drug therapy , Animals , Anticonvulsants/administration & dosage , Disease Models, Animal , Electroencephalography/drug effects , Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/physiopathology , Levetiracetam , Male , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacology , Piracetam/administration & dosage , Piracetam/pharmacology , Rats , Seizures/etiology , Seizures/physiopathology , Time Factors
6.
Epilepsy Behav ; 28(2): 232-40, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23773980

ABSTRACT

Several clinical and preclinical studies have focused on the relationship between epilepsy and psychological disturbances. Although behavior in some experimental models of epilepsy has been studied, only few of them can be considered as models of epilepsy and mood disorder comorbidity. Since several models of epilepsy or psychiatric disorders are already available, we wondered whether a mixture of the two could experimentally represent a valid alternative to study such comorbidity. Here, we present a possible experimental protocol to study drug effects and physiopathogenesis of psychiatric comorbidity in epileptic animals. Pentylentetrazol-kindled animals were subjected to the chronic mild stress (CMS) procedure; furthermore, we tested the effects of chronic lamotrigine treatment on the development of comorbidity. We found that epileptic-depressed animals showed more pronounced behavioral alterations in comparison to other mice groups, indicating that kindled animals develop more pronounced CMS-induced behavioral alterations than nonepileptic mice; lamotrigine was able to prevent the development of comorbidities such as anxiety, depression-like behavior, and memory impairment.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Epilepsy/physiopathology , Stress, Psychological/drug therapy , Stress, Psychological/physiopathology , Triazines/therapeutic use , Animals , Comorbidity , Disease Models, Animal , Epilepsy/chemically induced , Exploratory Behavior/drug effects , Food Preferences/drug effects , Lamotrigine , Male , Maze Learning/drug effects , Mice , Mice, Inbred C57BL , Pentylenetetrazole/toxicity , Statistics, Nonparametric , Sucrose/administration & dosage , Swimming/psychology , Time Factors
7.
J Alzheimers Dis ; 35(4): 833-46, 2013.
Article in English | MEDLINE | ID: mdl-23515019

ABSTRACT

Huperzine A (Hup-A), an alkaloid isolated from Huperzia serrata (Thunb.) Trevis. (Lycopodiaceae), acts as a selective inhibitor of acetylcholinesterase and shows memory-enhancing properties. Although Hup-A has shown promising expectation for Alzheimer's disease (AD) patients, controlled clinical trials supporting its use are limited. The aim of this work was to study in vivo, in an animal model of AD, the pharmacological activity of systemic administration of Hup-A on cortex- and hippocampus-dependent memory. With this purpose, a set of experiments was planned to evaluate attention, learning, working and spatial memory with respect to cortical and hippocampal electroencephalogram (EEG) theta rhythm during the object recognition test and Morris water maze in animals with lesion of the nucleus basalis of Meynert (NBM). In NBM-lesioned animals, compared with control, an increased theta power in the cortex and a reduced theta rhythm oscillation in the hippocampus were found. These EEG changes were correlated with worse performance in learning and memory tasks. In rats with damaged NBM, Hup-A (0.5 mg/kg i.p.) was able to restore EEG architecture, producing cortical desynchronization and reduction in theta power, while in the hippocampus the drug increased theta oscillation and reduced the impairment in attention/working memory as well as spatial navigation performance in the behavioral tasks. Taken together, the present data suggest that Hup-A is able to restore cholinergic cortico-hippocampal functional connectivity. In conclusion, the present results are in agreement with other experimental evidence that promote the clinical use of this natural drug.


Subject(s)
Alkaloids/pharmacology , Basal Nucleus of Meynert/pathology , Cerebral Cortex/drug effects , Excitatory Amino Acid Agonists/toxicity , Hippocampus/drug effects , Neural Pathways/drug effects , Sesquiterpenes/pharmacology , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/toxicity , Animals , Electroencephalography/drug effects , Electroencephalography Phase Synchronization/drug effects , Male , Maze Learning/drug effects , Memory, Short-Term/drug effects , Parasympathetic Nervous System/drug effects , Psychomotor Performance/drug effects , Rats , Rats, Wistar , Space Perception/drug effects
8.
Pharmacol Res ; 65(3): 285-96, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22107891

ABSTRACT

The renin-angiotensin system (RAS) exists in the brain and it may be involved in pathogenesis of neurological and psychiatric disorders including seizures. The aim of the present research was to evaluate the effects of some angiotensin-converting enzyme inhibitors (ACEi; captopril, enalapril, fosinopril and zofenopril), commonly used as antihypertensive agents, in the DBA/2 mice animal model of generalized tonic-clonic seizures. Furthermore, the co-administration of these compounds with some antiepileptic drugs (AEDs; carbamazepine, diazepam, felbamate, gabapentin, lamotrigine, phenobarbital, phenytoin, topiramate and valproate) was studied in order to identify possible positive interactions in the same model. All ACEi were able to decrease the severity of audiogenic seizures with the exception of enalapril up to the dose of 100mg/kg, the rank order of activity was as follows: fosinopril>zofenopril>captopril. The co-administration of ineffective doses of all ACE inhibitors with AEDs, generally increased the potency of the latter. Fosinopril was the most active in potentiating the activity of AEDs and the combination of ACEi with lamotrigine and valproate was the most favorable, whereas, the co-administrations with diazepam and phenobarbital seemed to be neutral. The increase in potency was generally associated with an enhancement of motor impairment, however, the therapeutic index of combined treatment of AEDs with ACEi was predominantly more favorable than control. ACEi administration did not influence plasma and brain concentrations of the AEDs studied excluding pharmacokinetic interactions and concluding that it is of pharmacodynamic nature. In conclusion, fosinopril, zofenopril, enalapril and captopril showed an additive anticonvulsant effect when co-administered with some AEDs, most notably carbamazepine, felbamate, lamotrigine, topiramate and valproate, implicating a possible therapeutic relevance of such drug combinations.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Anticonvulsants/therapeutic use , Captopril/analogs & derivatives , Captopril/pharmacology , Enalapril/pharmacology , Fosinopril/pharmacology , Seizures/drug therapy , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacology , Captopril/administration & dosage , Captopril/therapeutic use , Drug Synergism , Enalapril/administration & dosage , Enalapril/therapeutic use , Female , Fosinopril/administration & dosage , Fosinopril/therapeutic use , Male , Mice , Motor Activity/drug effects
9.
CNS Neurol Disord Drug Targets ; 10(7): 766-76, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21999733

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment due to neuronal death. Although the lost of cognitive function is the main problem for AD subjects, death occurs due to secondary issues such as concomitant infections, respiratory complications or multi-organ failure. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists of the N-methyl-D-aspartate receptor. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. Over the last 5 years, new targets were identified and innovative drugs against AD have been designed and developed. Worthy of mention are ß-secretase inhibitors, monoclonal antibodies against amyloid-ß-peptide and tau inhibitors. However, although promising beneficial effects were highlighted in the data from preclinical studies, only few of these new drugs improved cognitive functions for a significant time frame in AD subjects. Controversial is the therapeutic effect on AD obtained through the manipulation of the nitric oxide synthase/nitric oxide system since the potential toxic effects on brain function could overcome the beneficial effects. The aim of this review is to analyze from a pharmacologic point of view both old and new drugs developed for the treatment of AD. In addition, the risk/benefit ratio related to the modulation of the nitric oxide synthase/nitric oxide system in AD brain will be analyzed.


Subject(s)
Alzheimer Disease/drug therapy , Nitric Oxide/antagonists & inhibitors , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Animals , Humans , Nitric Oxide/metabolism
10.
Behav Brain Res ; 225(1): 373-6, 2011 Nov 20.
Article in English | MEDLINE | ID: mdl-21807031

ABSTRACT

To evaluate the effects of Vigabatrin (VGB) treatment, on both absence seizure and depressive-like behaviour development in the WAG/Rij rat model of absence seizures. Early long-term treatment with VGB could alter the development of absence pathology, by significantly reducing seizure generation and synchronization in contrast to its pro-absence effects observed after acute or subchronic administration. We have demonstrated the antidepressant effects of a sub-chronic treatment with VGB in both wistar and WAG/Rij rats. In contrast, following an early long-term treatment, VGB antidepressant effects were only observable in WAG/Rij rats. In conclusion, VGB has antiepileptogenic and antidepressant properties in the WAG/Rij rat model despite its pro-absence effects suggesting that epilepsy and depression, in this animal model, are directly related and that seizure development inhibition also reduces the development of depressive behaviour.


Subject(s)
Anticonvulsants/therapeutic use , Antidepressive Agents/therapeutic use , Depression/drug therapy , Epilepsy/drug therapy , Vigabatrin/therapeutic use , Analysis of Variance , Animals , Depression/complications , Disease Models, Animal , Electroencephalography/methods , Epilepsy/complications , Epilepsy/genetics , Immobility Response, Tonic/physiology , Male , Random Allocation , Rats , Rats, Mutant Strains , Rats, Wistar , Swimming/psychology
11.
Behav Brain Res ; 190(1): 22-32, 2008 Jun 26.
Article in English | MEDLINE | ID: mdl-18355933

ABSTRACT

The aim of present work was the evaluation of the effects on brain levels of nerve growth factor (NGF) and of its high-affinity tyrosine kinase A receptor (TrkA), induced in rats unilaterally lesioned at nucleus basalis magnocellularis (NBM), by treatment with choline pivaloyl ester (CPE). CPE was daily administered (60 micromol/Kg ip) during 3 weeks to rats selectively lesioned by AMPA infusion into right NBM; the intact left NBM serving as control. NGF levels were determined in cerebral cortex and hippocampus by Elisa assay. TrkA receptor expression was evaluated in right NBM by Western blotting analysis. CPE treatment significantly increased NGF levels in both hippocampus and neocortex in right NBM, compared with intact left counter-part and controls. Western blotting showed an evident enhancement in TrkA receptor expression in lesioned right NBM in comparison with intact left counter-part and controls. CPE treatment was also able to restore, in bilaterally NBM-lesioned rats, the disrupted cortical EEG and HVS activities as well as to reverse deficits in learning and memory in spatial navigation and probe trials, and cognitive capacities in object recognition task.


Subject(s)
Brain/metabolism , Cognition Disorders/drug therapy , Cyclopentanes/therapeutic use , Memory Disorders/drug therapy , Nerve Growth Factor/metabolism , Receptor, trkA/metabolism , Animals , Basal Nucleus of Meynert/drug effects , Basal Nucleus of Meynert/pathology , Behavior, Animal/drug effects , Brain/drug effects , Choline O-Acetyltransferase/metabolism , Cognition Disorders/etiology , Electroencephalography , Functional Laterality , Gene Expression Regulation/drug effects , Male , Maze Learning/drug effects , Memory Disorders/etiology , Nerve Growth Factor/genetics , Neuropsychological Tests , Neurotoxicity Syndromes/complications , Neurotoxicity Syndromes/pathology , Rats , Rats, Wistar , Reaction Time/drug effects , Receptor, trkA/genetics , Time Factors
12.
Pharmacol Biochem Behav ; 78(4): 667-73, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15301920

ABSTRACT

The electroencephalographic (EEG) effects of two choline pivaloyl esters, [2-(2,2-dimethylpropionyloxy)ethyl]trimethylammonium iodide (1) and [2-(2,2-dimethylpropionyloxy)ethyl]trimethylammonium 2,2-dimethylpropionate (2), were evaluated in scopolamine-treated or nucleus basalis magnocellularis (NBM) lesioned rats. In scopolamine-treated animals, Compounds 1 and 2 prevented or reduced EEG effects, such as increased amplitude of total spectra and high-voltage spindle (HVS) activity as well. Furthermore, choline esters showed a noticeable effectiveness in reversing the EEG changes produced in rats by AMPA-induced lesion of NBM. Indeed, Compounds 1 and 2 were able to induce EEG desynchronisation, a significant decrease in the total EEG power (0.25-16 Hz) and in the lower frequency delta and theta bands (0.25-3 and 3-6 Hz, respectively). The EEG effects produced by Compounds 1 and 2 were well comparable with that evoked by Tacrine, used as a reference compound. The results of the present work allow us to put forward the hypothesis that the EEG effects observed are most likely mediated through the stimulation of the cholinergic neurotransmission ensuing from enhanced cerebral levels of acetylcholine (ACh) consequent upon acetylcholinesterase (AChE) inhibition by choline pivaloyl esters.


Subject(s)
Basal Nucleus of Meynert/drug effects , Choline/analogs & derivatives , Choline/pharmacology , Electroencephalography/drug effects , Esters/pharmacology , Parasympatholytics/pharmacology , Scopolamine/pharmacology , Animals , Basal Nucleus of Meynert/anatomy & histology , Choline O-Acetyltransferase/metabolism , Dose-Response Relationship, Drug , Injections, Intraperitoneal , Male , Parasympathetic Nervous System/drug effects , Parietal Lobe/physiology , Rats , Rats, Wistar , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
13.
Neurosci Lett ; 356(3): 199-202, 2004 Feb 19.
Article in English | MEDLINE | ID: mdl-15036629

ABSTRACT

The effects of two choline pivaloyl esters, [2-(2,2-dimethylpropionyloxy)ethyl]trimethylammonium iodide (1) and [2-(2,2-dimethylpropionyloxy)ethyl]trimethylammonium 2,2-dimethylpropionate (2), on learning and memory impairments induced in rats by scopolamine or lesions of nucleus basalis magnocellularis (NBM) have been evaluated by object recognition and Morris water maze tests in comparison with Tacrine (THA). Both 1 and 2 restored discrimination in object recognition test for assessing working-episodic memory and improved spatial memory in scopolamine or NBM-lesioned rats as well. The positive effects produced by 1 and 2 on cognitive and memory deficits were well comparable with those evoked by THA, used as reference compound.


Subject(s)
Basal Nucleus of Meynert/drug effects , Cholinesterase Inhibitors/therapeutic use , Cognition Disorders/drug therapy , Memory Disorders/drug therapy , Propiophenones/therapeutic use , Quaternary Ammonium Compounds/therapeutic use , Acetylcholinesterase/metabolism , Analysis of Variance , Animals , Basal Nucleus of Meynert/injuries , Basal Nucleus of Meynert/physiopathology , Cell Count , Choline/analogs & derivatives , Choline/pharmacology , Choline/therapeutic use , Cognition Disorders/chemically induced , Cognition Disorders/physiopathology , Discrimination Learning/drug effects , Dose-Response Relationship, Drug , Drug Interactions , Esters/therapeutic use , Immunohistochemistry/methods , Male , Maze Learning/drug effects , Memory Disorders/chemically induced , Rats , Rats, Wistar , Scopolamine , Spatial Behavior/drug effects , Tacrine/pharmacology , Time Factors
14.
Neurosci Lett ; 335(3): 163-6, 2003 Jan 02.
Article in English | MEDLINE | ID: mdl-12531458

ABSTRACT

Herbicides, including paraquat, may produce neurodegenerative effect when given both peripherally and into the brain though the pathophysiological mechanism is still unknown. Microinfusion of paraquat into the Substantia Nigra (50 microg) produced increased motor activity, jumping and circling opposite to the injection site, associated with ECoG desynchronization, high voltage epileptogenic spikes, and with neuropathological effects. These effects were accompanied by increase of malondialdehyde (MDA) levels in the Substantia Nigra, suggesting that paraquat was able to induce oxidative stress when injected directly into the rat brain. Pre-treatment of rats with M40401, a non peptidyl superoxide dismutase (SOD) mimetic given directly into the Substantia Nigra or i.p. prevented both behavioural, electrocorticogram and neuropathological effects and MDA elevation. Taken together, these results demonstrate that paraquat produces brain damage via abnormal formation of oxygen free radicals and that this effect may be counteracted by novel SOD mimetics.


Subject(s)
Herbicides/toxicity , Neuroprotective Agents/pharmacology , Organometallic Compounds/pharmacology , Oxidative Stress , Paraquat/toxicity , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Superoxide Dismutase/metabolism , Animals , Electrocardiography/drug effects , Epilepsy/chemically induced , Epilepsy/prevention & control , Free Radicals/metabolism , Male , Malondialdehyde/metabolism , Motor Activity/drug effects , Neurons/drug effects , Neurons/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar , Substantia Nigra/enzymology , Substantia Nigra/pathology , Superoxide Dismutase/pharmacology
15.
Bioorg Med Chem Lett ; 12(20): 2899-905, 2002 Oct 21.
Article in English | MEDLINE | ID: mdl-12270172

ABSTRACT

Pivaloyl-choline iodide 1 interactions with acetylcholinesterase (AChE) have been studied by theoretical and enzymatic methods. An integrated computational approach has clearly shown a substrate rather than inhibitory profile for 1. Enzymatic experiments have also supported the same theoretical conclusion indicating that AChE was able to hydrolyze 1 to choline.


Subject(s)
Acetylcholinesterase/chemistry , Choline/analogs & derivatives , Choline/pharmacology , Amino Acid Sequence , Binding Sites , Chemical Phenomena , Chemistry, Physical , Hydrolysis , Kinetics , Ligands , Magnetic Resonance Spectroscopy , Models, Molecular , Protein Conformation
SELECTION OF CITATIONS
SEARCH DETAIL
...